Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025)

Silence Therapeutics has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $168000.0 for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $168000.0, down 45.1% year-over-year; the trailing twelve-month figure through Dec 2025 was $168000.0 (down 45.1% YoY), and the FY2025 annual result was $168000.0, down 45.1% from the prior year.
• Current Deferred Revenue came in at $168000.0 for Q4 2025 at Silence Therapeutics, down from $301000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $10.4 million in Q4 2022 to a low of $168000.0 in Q4 2025.
• The 5-year median for Current Deferred Revenue is $424500.0 (2025), against an average of $3.0 million.
• Across the five-year window, Current Deferred Revenue surged 81.6% in 2022 and sank 95.22% in 2024, its largest moves.
• Silence Therapeutics' Current Deferred Revenue stood at $5.7 million in 2021, then soared by 81.6% to $10.4 million in 2022, then slumped by 38.39% to $6.4 million in 2023, then slumped by 95.22% to $306000.0 in 2024, then plunged by 45.1% to $168000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $168000.0 (Q4 2025), $301000.0 (Q3 2025), and $457000.0 (Q2 2025), per Business Quant data.